X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/the-european-commission-approves-label-update-for-takhzyro-lanadelumab-expanding-its-use-to-a-broader-group-of-paediatric-patients-with-recurrent-attacks-of-hereditary-angioedema-hae-301992261.html
https://www.prnewswire.com/news-releases/takeda-receives-positive-chmp-opinion-recommending-approval-of-lanadelumab-for-routine-prevention-of-recurrent-attacks-of-hereditary-angioedema-hae-in-patients-aged-2-years-and-older-301936251.html
https://www.takeda.com/newsroom/newsreleases/2023/takeda-to-present-multiple-new-data-analyses-at-2023-aaaai-annual-meeting-including-spring-study-of-takhzyro-in-pediatric-patients-with-hereditary-angioedema-hae/
https://www.businesswire.com/news/home/20221004006135/en/U.S.-Food-and-Drug-Administration-Accepts-Takeda%E2%80%99s-Supplemental-Biologics-License-Application-for-Use-of-TAKHZYRO%C2%AE-lanadelumab-flyo-to-Prevent-Hereditary-Angioedema-HAE-Attacks-in-Children-2-Years-of-Age-and-Older
https://www.globenewswire.com/news-release/2021/11/05/2328408/29446/en/BioCryst-Presents-New-Data-Showing-Sustained-Reduction-of-HAE-Attack-Rates-and-Improved-Patient-Satisfaction-After-Patients-Switch-to-ORLADEYO-berotralstat.html
https://www.takeda.com/newsroom/newsreleases/2020/final-results-from-the-phase-3-help-study-open-label-extension-support-takhzyro-lanadelumab-flyo-injection-as-a-long-term-preventive-treatment-option-in-patients-with-hereditary-angioedema/
https://www.globenewswire.com/news-release/2020/06/06/2044595/0/en/Hereditary-Angioedema-Patients-Report-Breakthrough-Attacks-on-Current-Injectable-Infused-Prophylaxis-Medication.html
https://www.takeda.com/newsroom/newsreleases/2020/new-data-from-the-phase-3-help-study-open-label-extension-evaluate-the-long-term-safety-and-efficacy-of-takhzyro-lanadelumab-in-reducing-hereditary-angioedema-attacks/
http://www.pharmatimes.com/news/nice_recommends_takhzyro_1301906
https://www.reuters.com/article/us-india-ecigarettes/india-bans-e-cigarettes-in-setback-for-juul-philip-morris-idUSKBN1W315Y?feedType=RSS&feedName=healthNews
https://www.fiercepharma.com/pharma/most-expensive-meds-u-s-topped-by-novartis-and-spark-gene-therapies
https://endpts.com/biocryst-shares-are-blasted-as-a-phiii-hae-success-underwhelms-analysts/
https://www.ema.europa.eu/documents/overview/takhzyro-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761090
http://www.pharmatimes.com/news/shires_lanadelumab_shown_to_significantly_cut_hae_attacks_1260707
https://www.fiercepharma.com/pharma/shire-s-takhzyro-gets-off-to-hot-start-too-boost-immunology-sales-ahead-takeda-buyout
https://endpts.com/takeda-is-ready-to-auction-off-a-phiii-favorite-at-shire-to-clear-the-last-hurdles-to-a-62b-buyout/
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018
https://www.ema.europa.eu/documents/press-release/new-medicine-hereditary-angioedema-rare-disease-causing-swelling-beneath-skin_en.pdf
https://www.fiercepharma.com/marketing/panel-backing-for-key-shire-drug-beefs-up-takeda-s-case-for-its-62b-buyout
https://www.reuters.com/article/us-shire-ema-takhzyro/shires-drug-for-rare-swelling-disorder-wins-european-panel-green-light-idUSKCN1MT1SQ
Market Place
Share 
